Please assess the completion status of the following clinical trial:

Trial Title: Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be \< 45 years of age and ≥ 28 days old~* Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective~* The individual patient's disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival~* Left ventricular ejection fraction \>45%~* Transaminases and bilirubin \< twice the upper limit of the normal range~* Creatinine clearance \> 60mls/min~* Comorbidity index of 0 or 1~Exclusion Criteria:~* Patients with a suitably matched sibling donor or 10/10 unrelated volunteer donor available within an acceptable time period.~* Pregnancy or breastfeeding.~* Evidence of HIV or HTLV (I+II) infection or known HIV or HTLV positive serology~* Current active serious infection, in particular uncontrolled fungal infection -Previous irradiation that precludes the safe administration of an additional dose of 13- 14.4 Gy of total body irradiation (TBI) in patients aged 2-45 years~* Prior autograft~* CML in first chronic phase responding to Imatinib or refractory blast crisis~* Patients with acute leukaemia in morphological relapse/ persistent disease (defined as \> 5% blasts in normocellular bone marrow)~* Patients with acute myeloid leukaemia with relapse/persistent disease unresponsive to re-induction chemotherapy (defined as \>20% blasts in normocellular bone marrow)~* Malignant disease that is refractory to or progressive on salvage therapy~* Myelofibrosis.~* Aplastic anaemia

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine + Cyclophosphamide + TBI (Type: EXPERIMENTAL): Patients aged 2-45 years (excluding AML, JMML and MDS patients aged \<16 years) will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Fludarabine 25mg/m\^2/day day -8 to -6 (total 75mg/m\^2) Cyclophosphamide 60mg/kg day -7 and -6 (total 120mg/kg) Total body irradiation 13 - 14.4Gy in 6-8 fractions
- Busulfan + Cyclophosphamide + Melphalan (Type: EXPERIMENTAL): Patients aged \< 2 years and AML, JMML and MDS patients \<16 years will receive an umbilical cord blood transplant using a myeloablative conditioning regimen comprising:~Busulfan 3.2mg/kg/day in 2 or 4 doses per day, days -9 to -6 (total 12.8mg/kg). Cyclophosphamide 60mg/kg days -4 and -3 (total 120mg/kg) Melphalan 140mg/m\^2 day -2

Based on this trial design, predict the completion outcome and termination type (if applicable).